<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2013-05-27" updated="2020-01-02">
  <drugbank-id primary="true">DB08886</drugbank-id>
  <name>Asparaginase Erwinia chrysanthemi</name>
  <description>Erwinaze (asparaginase _Erwinia_ _chrysanthemi_) contains an asparaginase specific enzyme derived from _Erwinia_ _chrysanthemi_ [L149]. Specifically, this L-asparaginase is a tetrameric enzyme consisting of four identical subunits, each having a molecular weight of about 35 kDa [L149]. The activity of Erwinaze is expressed in terms of International Units. It is an antineoplastic agent and was FDA approved in November 19, 2011 [L149].</description>
  <cas-number>1349719-22-7</cas-number>
  <unii>D733ET3F9O</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7464</ref-id>
        <pubmed-id>20824725</pubmed-id>
        <citation>Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH: L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011 Jan 15;117(2):238-49. doi: 10.1002/cncr.25489. Epub 2010 Sep 7.</citation>
      </article>
      <article>
        <ref-id>A14437</ref-id>
        <pubmed-id>18421047</pubmed-id>
        <citation>Yang L, Panetta JC, Cai X, Yang W, Pei D, Cheng C, Kornegay N, Pui CH, Relling MV: Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol. 2008 Apr 20;26(12):1932-9. doi: 10.1200/JCO.2007.13.8404.</citation>
      </article>
      <article>
        <ref-id>A32012</ref-id>
        <pubmed-id>15059133</pubmed-id>
        <citation>Pinheiro JP, Boos J: The best way to use asparaginase in childhood acute lymphatic leukaemia--still to be defined? Br J Haematol. 2004 Apr;125(2):117-27. doi: 10.1111/j.1365-2141.2004.04863.x.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L149</ref-id>
        <title>Link</title>
        <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125359lbl.pdf</url>
      </link>
      <link>
        <ref-id>L150</ref-id>
        <title>Link</title>
        <url>http://webprod5.hc-sc.gc.ca/dpd-bdpp/info.do?code=61174&amp;lang=eng</url>
      </link>
      <link>
        <ref-id>L1447</ref-id>
        <title>Electronic Medicines Compendium ERWINASE (Erwinia L-asparaginase), 10000 Units/vial, Lyophilisate for Solution for Injection Monograph</title>
        <url>https://www.medicines.org.uk/emc/product/4979</url>
      </link>
      <link>
        <ref-id>L1448</ref-id>
        <title>BC Cancer Asparaginase Monograph</title>
        <url>http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Asparaginase_monograph_1June2013_formatted.pdf</url>
      </link>
      <link>
        <ref-id>L1452</ref-id>
        <title>Pegylated l-asparaginase: Protein Sequence of Erwinia Asparaginase</title>
        <url>https://patents.google.com/patent/EP2451486A1</url>
      </link>
      <link>
        <ref-id>L1453</ref-id>
        <title>Genbank Accession No. CAA32884: L-asparaginase [Dickeya chrysanthemi]</title>
        <url>https://www.ncbi.nlm.nih.gov/protein/CAA32884.1</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Asparaginase _Erwinia_ _chrysanthemi_ is for the treatment of patients with acute lymphoblastic leukemia (ALL) that have developed a hypersensitivity to E. coli-derivied asparaginase [L149]. It is a component of a multi-agent chemotherpeutic regimen [L149] for the treatment of the aforementioned disease and is considered second- or third- line treatment in European and American protocols [A7464]. </indication>
  <pharmacodynamics>Asparagine is ordinarily found incorporated into most endogenous proteins [L1447]. In its absence however, protein synthesis is halted - which in turn also results in the inhibition of the RNA and DNA synthesis necessary for cellular proliferation [L1447]. &#13;
&#13;
One commonality between Acute Lymphoblastic Leukaemia (ALL), Acute Myeloid Leukaemia (AML), and Non-Hodgkin's Lymphoma (especially the lymphoblastic form) is the absence of asparagine synthetase activity in the neoplastic cells associated with these conditions [L1447]. These neoplastic cells are subsequently dependent upon exogenous asparagine for their proliferation [L1447].&#13;
&#13;
The anti-neoplastic function of L-asparaginase is consequently a result of the sustained depletion of exogenous asparagine [L1447]. In particular, _Erwinia_ L-asparaginase catalyses the deamination of asparagine to aspartic acid and the release of an ammonia molecule [L1447].&#13;
&#13;
In addition, asparaginase also demonstrates a significant glutaminase activity in which it is capable of catalyzing the deamination of glutamine to glutamate and the release of an ammonia molecule [L1447]. Since glutamine may lead to alternative asparagine synthesis, the ability for asparaginase to facilitate glutamine depletion may complement asparagine depletion [L1447]. The exact potential to such glutaminase activity, however, remains unknown [L1447].</pharmacodynamics>
  <mechanism-of-action>Asparaginase _Erwinia_ _chrysanthemi_ catalyzes the deamidation of asparagine to aspartic acid and ammonia, resulting in a reduction in circulating levels of exogenous asparagine in the plasma [L149]. The mechanism of action of _Erwinia_ asparaginase is thought to be based on the inability of leukemic cells to synthesize asparagine due to lack of asparagine synthetase activity, resulting in cytotoxicity specific for leukemic cells that depend on an exogenous source of the amino acid asparagine for their protein metabolism and survival [L149].</mechanism-of-action>
  <toxicity>_Erwinia_ asparaginase is contraindicated in individuals who: (a) have a history of serious hypersensitivity reactions to _Erwinia_ asparaginase, including anaphylaxis, (b) have a history of serious pancreatitis with prior L-asparaginase therapy, (c) have a history of serious thrombosis with prior L-asparaginase therapy, and (d) have a history of serious hemorrhagic events with prior L-asparaginase therapy. [L149, FDA Label]&#13;
&#13;
5% of patients in clinical trials have experienced grade 3 and 4 hypersensitivity reactions after being administered _Erwinia_ asparaginase [L149, FDA Label].&#13;
&#13;
4% of patients in clinical trials have experienced pancreatitis after using _Erwinia_ asparaginase, where severe pancreatitis serves as a contraindication for continued use of _Erwinia_ asparaginase [L149, FDA Label].&#13;
&#13;
5% of patients in clinical trials using _Erwinia_ asparaginase reported experiencing glucose intolerance that was in some cases irreversible [L149, FDA Label].&#13;
&#13;
Serious thrombotic events like sagittal sinus thrombosis and pulmonary embolism have been reported with _Erwinia_ asparaginase therapy [L149, FDA Label]. After a 2 week course of _Erwinia_ asparaginase therapy by i.m. administration, a majority of patients demonstrated decreased fibrinogen, protein C activity, and anti-thrombin III [L149, FDA Label].&#13;
&#13;
The most common adverse reactions (incidence of 1% or greater) associated with _Erwinia_ asparaginase treatment include systemic  hypersensitivity, hyperglycemia, abnormal transaminase levels, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain or discomfort, and diarrhea [L149, FDA Label].&#13;
&#13;
Patients using _Erwinia_ asparaginase may develop anti-drug antibodies to the medicine after repeated use [L149, L1447]. The presence of antibodies specific to _Erwinia_ asparaginase is linked with a higher probability of hypersensitivity reactions in patients who are administered _Erwinia_ asparaginase via i.v. infusion compared to i.m. administration [L149].&#13;
&#13;
There are no adequate studies of _Erwinia_ asparaginase use in pregnant women [L149, FDA Label]. This medication belongs in pregnancy category C and _Erwinia_ asparaginase should only be used during pregnancy if the potential benefits justifies the potential risk to the fetus [L149, FDA Label].&#13;
&#13;
It is not known whether _Erwinia_ asparaginase is secreted in human milk, but the potential for serious adverse reactions in nursing infants from _Erwinia_ asparaginase means a decision must be made whether to discontinue nursing or to discontinue _Erwinia_ asparaginase therapy, taking into account the importance of this drug therapy to the mother [L149, FDA Label].&#13;
&#13;
Clinical studies have administered _Erwinia_ asparaginase to patients from ages 1 to 18 [L149].&#13;
&#13;
The safety and efficacy of _Erwinia_ asparaginase has not been studied in geriatric patients [L149].&#13;
&#13;
No long-term carcinogenicity studies in animals have been performed with _Erwinia_ asparaginase [L149]. No studies that assess the mutagenic potential of _Erwinia_ asparaginase have been performed either [L149].&#13;
&#13;
Fertility and early embryonic development studies in rats demonstrate asparaginase Erwinia chrysanthemi has no effect on male or female fertility when administered i.m. at doses of up to 2000 IU/kg (about 50% of the recommended human dose, after adjustment for total body surface area) every other day for a total of 35 doses [L149]. Data for males included decreased sperm count at doses in excess of 500 IU/kg (approximately 12% of the recommended human dose) [L149].</toxicity>
  <metabolism>At the moment, conclusive data regarding the metabolism and elimination of asparaginase has not yet been developed [L1448, A32012]</metabolism>
  <absorption>The absorption of _Erwinia_ asparaginase is predominantly via denaturation followed by peptidase digestion within GI tract [L1448].</absorption>
  <half-life>The elimination half-life of _Erwinia_ asparaginase administered via i.m. injection is 16 hours and follows first-order kinetics [FDA Label]. Compared to E.coli-asparaginase, it has a lower half-life [FDA Label] so higher and more frequent doses are necessary. Similarly, the half-life of _Erwinia_ asparaginase after i.v. infusion is approximately 6.4 +/- 0.5 hours [L1447] and also follows first-order kinetics [FDA Label].</half-life>
  <protein-binding>No specific information regarding protein binding has been developed at the moment [L1448]. Nevertheless, with repeated use _Erwinia_ asparaginase may be bound by specific antibodies and eliminated [L1447].</protein-binding>
  <route-of-elimination>Formally conclusive findings regarding the elimination of _Erwinia_ asparaginase have unfortunately not yet been established. However, some studies posit that the drug may possibly be eliminated using the reticuloendothelial system [L1448].</route-of-elimination>
  <volume-of-distribution>The volume of distribution for _Erwinia_ asparaginase is 5 L/m2 [L1448]. The partitioning of Erwinia L-asparaginase between lymph and blood shows that this enzyme, in contrast to the E. coli derivative, does not penetrate the capillary endothelium well&#13;
because negligible amounts are found in the lymph [FDA Label]. Ultimately, although L-asparaginase is capable of penetrating through to the cerebrospinal fluid to a small degree [L1447] and is also found in limited quantities in lymph [L1447, FDA Label], the drug subsequently seems to confine itself mainly to the blood compartment of man [FDA Label].</volume-of-distribution>
  <clearance>The clearance of _Erwinia_ asparaginase is given as 3.4 mL/min/m2 [L1448].</clearance>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Asparaginase (Erwinia)</synonym>
    <synonym language="english" coder="">Asparaginase Erwinia chrysanthemi</synonym>
    <synonym language="english" coder="ban">Crisantaspase</synonym>
    <synonym language="english" coder="">Erwinia asparaginase</synonym>
    <synonym language="english" coder="">Erwinia chrysanthemi</synonym>
    <synonym language="english" coder="">L-asparaginase (Erwinia)</synonym>
  </synonyms>
  <products>
    <product>
      <name>Erwinase</name>
      <labeller>Jazz Pharmaceuticals France Sas</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02237815</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Erwinaze</name>
      <labeller>Jazz Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>57902-249</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-11-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>10000 [iU]/1mL</strength>
      <route>Intramuscular; Intravenous</route>
      <fda-application-number>BLA125359</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Erwinaze</name>
      <ingredients>Asparaginase Erwinia chrysanthemi</ingredients>
    </mixture>
    <mixture>
      <name>Erwinase</name>
      <ingredients>Asparaginase Erwinia chrysanthemi</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Asparaginase</category>
      <mesh-id>D001215</mesh-id>
    </category>
    <category>
      <category>Asparagine-specific Enzyme</category>
      <mesh-id/>
    </category>
    <category>
      <category>Thyroxine-binding globulin inhibitors</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intramuscular; Intravenous</route>
      <strength>10000 [iU]/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes>
    <ahfs-code>10:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB08886.pdf?1519686303</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB08886.pdf?1519678462</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The serum concentration of Dexamethasone can be increased when it is combined with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The therapeutic efficacy of Methotrexate can be decreased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The risk or severity of liver damage can be increased when Asparaginase Erwinia chrysanthemi is combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The therapeutic efficacy of Phenytoin can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>The therapeutic efficacy of Liothyronine can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The therapeutic efficacy of Levothyroxine can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The therapeutic efficacy of Mephenytoin can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The therapeutic efficacy of Carbamazepine can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The therapeutic efficacy of Furosemide can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>The therapeutic efficacy of Nitrofurantoin can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>The therapeutic efficacy of Ethotoin can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The therapeutic efficacy of Meclofenamic acid can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The therapeutic efficacy of Heparin can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>The therapeutic efficacy of Dantrolene can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The therapeutic efficacy of Fosphenytoin can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>The therapeutic efficacy of Liotrix can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>The therapeutic efficacy of Enzalutamide can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The therapeutic efficacy of Etofenamate can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12425</drugbank-id>
      <name>Liothyronine I-131</name>
      <description>The therapeutic efficacy of Liothyronine I-131 can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13396</drugbank-id>
      <name>Neocitrullamon</name>
      <description>The therapeutic efficacy of Neocitrullamon can be increased when used in combination with Asparaginase Erwinia chrysanthemi.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;Protein sequence for asparaginase (Erwinia chrysanthemi) monomer
ADKLPNIVILATGGTIAGSAATGTQTTGYKAGALGVDTLINAVPEVKKLANVKGEQFSNM
ASENMTGDVVLKLSQRVNELLARDDVDGVVITHGTDTVEESAYFLHLTVKSDKPVVFVAA
MRPATAISADGPMNLLEAVRVAGDKQSRGRGVMVVLNDRIGSARYITKTNASTLDTFKAN
EEGYLGVIIGNRIYYQNRIDKLHTTRSVFDVRGLTSLPKVDILYGYQDDPEYLYDAAIQH
GVKGIVYAGMGAGSVSVRGIAGMRKAMEKGVVVIRSTRTGNGIVPPDEELPGLVSDSLNP
AHARILLMLALTRTSDPKVIQEYFHTY</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Molecular Weight</kind>
      <value>140000.0</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C1546H2510N432O476S9</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910380</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D02997</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>X12746</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>P06608</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Asparaginase</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1863514</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/erwinaze-drug.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/monograph/asparaginase-erwinia-chrysanthemi.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers>
    <carrier position="1">
      <id>BE0000537</id>
      <name>Thyroxine-binding globulin</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P05543" source="Swiss-Prot">
        <name>Thyroxine-binding globulin</name>
        <general-function>Serine-type endopeptidase inhibitor activity</general-function>
        <specific-function>Major thyroid hormone transport protein in serum.</specific-function>
        <gene-name>SERPINA7</gene-name>
        <locus>Xq22.2</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-20</signal-regions>
        <theoretical-pi>6.27</theoretical-pi>
        <molecular-weight>46324.12</molecular-weight>
        <chromosome-location>X</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11583</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SERPINA7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M14091</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>338697</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05543</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>THBG_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Serpin A7</synonym>
          <synonym>T4-binding globulin</synonym>
          <synonym>TBG</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016123|Thyroxine-binding globulin
MSPFLYLVLLVLGLHATIHCASPEGKVTACHSSQPNATLYKMSSINADFAFNLYRRFTVE
TPDKNIFFSPVSISAALVMLSFGACCSTQTEIVETLGFNLTDTPMVEIQHGFQHLICSLN
FPKKELELQIGNALFIGKHLKPLAKFLNDVKTLYETEVFSTDFSNISAAKQEINSHVEMQ
TKGKVVGLIQDLKPNTIMVLVNYIHFKAQWANPFDPSKTEDSSSFLIDKTTTVQVPMMHQ
MEQYYHLVDMELNCTVLQMDYSKNALALFVLPKEGQMESVEAAMSSKTLKKWNRLLQKGW
VDLFVPKFSISATYDLGATLLKMGIQHAYSENADFSGLTEDNGLKLSNAAHKAVLHIGEK
GTEAAAVPEVELSDQPENTFLHPIIQIDRSFMLLILERSTRSILFLGKVVNPTEA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016124|Thyroxine-binding globulin (SERPINA7)
ATGTCACCATTCCTGTATCTGGTTCTCTTGGTACTTGGGCTTCATGCTACAATCCACTGT
GCATCACCTGAAGGCAAAGTAACAGCCTGCCATTCATCCCAACCAAATGCCACTCTCTAC
AAGATGTCATCCATTAATGCTGACTTTGCATTCAATCTGTACCGGAGGTTCACTGTGGAG
ACCCCAGATAAGAACATCTTCTTTTCCCCTGTGAGCATTTCTGCAGCTTTGGTTATGCTT
TCCTTTGGGGCCTGCTGCAGCACCCAAACTGAGATTGTGGAGACCTTGGGGTTCAACCTC
ACAGACACTCCAATGGTAGAGATCCAGCATGGCTTCCAGCATCTGATCTGTTCACTGAAT
TTTCCAAAGAAGGAACTGGAATTGCAGATAGGAAATGCCCTCTTCATTGGCAAGCATCTG
AAACCACTGGCAAAGTTCTTGAATGATGTCAAGACCCTCTATGAGACTGAAGTCTTTTCT
ACCGACTTCTCCAACATTTCTGCAGCCAAGCAGGAGATTAACAGTCATGTGGAGATGCAA
ACCAAAGGGAAAGTTGTGGGTCTAATTCAAGACCTCAAGCCAAACACCATCATGGTCTTA
GTGAACTATATTCACTTTAAAGCCCAGTGGGCAAATCCTTTTGATCCATCCAAGACAGAA
GACAGTTCCAGCTTCTTAATAGACAAGACCACCACTGTTCAAGTGCCCATGATGCACCAG
ATGGAACAATACTATCACCTAGTGGATATGGAATTGAACTGCACAGTTCTGCAAATGGAC
TACAGCAAGAATGCTCTGGCACTCTTTGTTCTTCCCAAGGAGGGACAGATGGAGTCAGTG
GAAGCTGCCATGTCATCTAAAACACTGAAGAAGTGGAACCGCTTACTACAGAAGGGATGG
GTTGACTTGTTTGTTCCAAAGTTTTCCATTTCTGCCACATATGACCTTGGAGCCACACTT
TTGAAGATGGGCATTCAGCATGCCTATTCTGAAAATGCTGATTTTTCTGGACTCACAGAG
GACAATGGTCTGAAACTTTCCAATGCTGCCCATAAGGCTGTGCTGCACATTGGTGAAAAG
GGAACTGAAGCTGCAGCTGTCCCTGAAGTTGAACTTTCGGATCAGCCTGAAAACACTTTC
CTACACCCTATTATCCAAATTGATAGATCTTTCATGTTGTTGATTTTGGAGAGAAGCACA
AGGAGTATTCTCTTTCTAGGGAAAGTTGTGAACCCAACGGAAGCGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00079</identifier>
            <name>Serpin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>hormone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to corticosterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to peptide hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to prostaglandin E</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin A</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thyroid hormone transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
  </carriers>
  <transporters/>
</drug>